Site Search

... innovation needs to be considered from the genesis of targeted therapies. It’s well-documented that patients are missing key opportunities for biomarker testing, which looks for specific mutations of a cancer to determine the most effective therapy for their particular cancer. As we have learned ... is reaching every patient.  It’s equally important to consider patient access to targeted therapies. Assuming a patient has had appropriate biomarker testing, patient access to the therapies indicated by this testing is another potential barrier. Our health care system has to find ways ...

... products. We will be making the following fact-based policies a priority and ask for your support:   Ensuring Access to Quality Care Access to Biomarker Testing: ACS CAN will advocate for House Bill 180, which improves coverage of comprehensive biomarker testing. Progress in improving cancer outcomes increasingly involves the use of precision medicine, which uses information about a ...

... and comprehensive health insurance including Medicaid and will support efforts to curb the availability of inadequate health plans. Access to Biomarker Testing: ACS CAN will advocate for improved coverage of comprehensive biomarker testing. Progress in improving cancer outcomes increasingly involves the use of precision medicine, which uses information about a ...

... insurance can find themselves with medical debt. The problem for these patients is that their insurance may not cover medically appropriate testing and treatments. This forces many New Jerseyans to choose between their physical and financial health. For example, some health insurance plans may not cover the biomarker testing that a patient needs. This testing is a game-changer in the fight against cancer and an essential step in accessing precision ... looking to change that and increase access to this revolutionary testing by requiring state-regulated health plans, including Medicaid, to cover biomarker testing for patients who can benefit. “As we pursue the aforementioned opportunities to assist current patients, we must also consider ...